Otsuka Pharmaceutical Co Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Otsuka Pharmaceutical Co Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH7246D
  • |
  • Pages: 96
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Otsuka Pharmaceutical Co Ltd (OPC), a subsidiary of Otsuka Holdings Co Ltd is a provider of healthcare products. The company offers products which include pocari sweat, pocari sweat ion water, oronamin c, calorie mate, nature made, jerubure, jarinea, five mini, amino-value, enerugen, jog mate protein jelly, metro mint, the calcium, oronine and new sararin, among others. Its pharmaceutical products are used in the areas of central nervous system, cardiovascular, circulatory disease, infectious diseases, kidney, digestive disease, ophthalmology and dermatology. The company operates in the US, Japan, Belgium, Australia, the UK, Denmark, and others. OPC is headquartered in Tokyo, Japan.

Otsuka Pharmaceutical Co Ltd-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 6

Otsuka Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Otsuka Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Otsuka Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Otsuka Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Otsuka Pharmaceutical Co Ltd, Medical Devices Deals, 2012 to YTD 2018 11

Otsuka Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Otsuka Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deal Details 16

Partnerships 16

Takara Bio Enters into Co-Development Agreement with Otsuka Pharma 16

Ribomic Enters into Agreement with Seikagaku 17

Medibio Enters into Agreement with Otsuka Pharma 18

Ribomic Enters into Research Agreement with Astellas Pharma 19

Ribomic Enters into Research Agreement with Evec 20

Cambridge Isotope Laboratories Enters into Agreement with IROA Technologies 21

Otsuka Pharma Enters into Co-Development Agreement with NEC 22

RIKEN and Otsuka Pharma Forms Joint Venture 23

Earth Chemical to Enter into Agreement with Taiko Pharma 24

Astex Pharma Enters into Agreement with Genentech 25

Ariad Pharma Enters into Co-Marketing Agreement with Otsuka Pharma for Iclusig 26

Ribomic Extends Research Agreement with Otsuka Pharma 28

Probi Enters into Co-Marketing Agreement with Pharmavite 29

Horizon Discovery Enters into Development and Commercialization Agreement with Otsuka Pharma 30

Otsuka Enters Into Co-Promotion Agreement With Takeda For TAK-438 31

Lundbeck Enters Into Co-Development Agreement With Otsuka Pharma For Lu AF20513 33

Lundbeck Enters Into Co-Development Agreement With Otsuka Pharma 34

Avanir Pharma Enters Into Agreement With Merck To Promote Diabetes Drugs 35

Otsuka Pharma Enters Into Co-Promotion Agreement Lundbeck For Abilify 37

Otsuka Pharma Forms Joint Venture With Abdi Ibrahim To Market Otsuka's Drugs In Turkey 38

Astex Pharma, Cancer Research Technology And Institute of Cancer Research Enter Into Epigenetic Drug Discovery Agreement 39

Otsuka Pharma Amends Co-Development Agreement With UCB 41

Licensing Agreements 43

Otsuka Pharma Enters into Licensing Agreement with X-Chem 43

Mylan Pharma Enters into Licensing Agreement with Otsuka Novel Products for Delamanid 44

R-Pharm Enters into Licensing Agreement with Otsuka Novel Products 45

Otsuka Pharma Enters into Licensing Agreement with Teva Pharma for TEV-48125 46

Otsuka Pharma to Enter into Licensing Agreement with Ribomic for RBM001 47

Otsuka Pharma Enters into Licensing Agreement with Akebia Therapeutics for Vadadustat 48

Otsuka Pharma Enters into Licensing Agreement with Akebia Therapeutics 50

Otsuka Pharma Enters into Licensing Agreement with Takara Bio 51

Medimetriks Pharma Enters into Licensing Agreement with Otsuka Pharma for OPA-15406 52

NuView Life Sciences Enters into Licensing Agreement with Otsuka Pharma for VPAC1 Biomarker 53

Fujimoto Pharma Enters into Licensing Agreement with Ribomic 54

Lundbeck Enters Into Licensing Agreement With Otsuka Pharma For Lu AE58054 55

Concert Pharma Enters Into Licensing Agreement With AVANIR Pharma For Neurology And Psychiatry Drugs 56

Otsuka Pharma Enters Into Licensing Agreement With Eisai 58

Proteus Biomedical Enters Into Licensing Agreement With Otsuka Pharma 59

Otsuka Pharma Enters Into Licensing Agreement With Kyowa Hakko Kirin For Saxagliptin 60

Equity Offering 61

Taiko Pharma to Raise Funds through Private Placement of Shares 61

Avanir Pharma Raises USD230 Million in Public Offering of Shares 62

Ribomic Raises USD26 Million in IPO of Shares 64

GlycoNex Announces Private Placement Of Shares For USD 9.2 Million 66

Avanir Pharma Files Registration Statement For Public Offering Of Securities For Up To USD 150 Million 67

Avanir Pharma Increases Size Of Private Placement Of Shares For USD 80 Million 68

Astex Pharma Files Registration Statement For Public Offering Of Securities For USD 200 Million 69

Asset Transactions 71

Tolero Pharma Acquires Drug Development Assets From Astex Pharma 71

Acquisition 73

Otsuka Pharma Acquires Visterra for USD430 Million 73

Otsuka Pharma to Acquire Neurovance 74

Otsuka Acquires Avanir Pharma for USD3.5 Billion 75

Egypt Otsuka Pharmaceutical to Acquire 80% Stake in Ateco Pharma 77

Otsuka Pharma Completes Acquisition Of Astex Pharma For USD 886 Million 78

Gimv Sells Stake In Astex Therapeutics 80

China Otsuka Pharmaceutical Acquires Dalian Taihua Pharmaceutical 81

Otsuka Pharmaceutical Co Ltd-Key Competitors 82

Otsuka Pharmaceutical Co Ltd-Key Employees 83

Otsuka Pharmaceutical Co Ltd-Locations And Subsidiaries 84

Head Office 84

Other Locations & Subsidiaries 84

Joint Venture 90

Recent Developments 91

Product News 91

Aug 21, 2018: TrialAssure partners with Otsuka Pharmaceutical to provide clinical trial disclosure reporting system for global pipeline 91

Apr 25, 2018: Proteus Digital Health Announces Digital Medicines Pipeline Development and Expansion into Oncology 92

Other Significant Developments 93

May 09, 2018: Otsuka Pharmaceutical Development & Commercialization Develops Relapse Risk Assessment For Schizophrenia Patients (RASP): A New Self-Report Screening Tool 93

Feb 28, 2018: Otsuka Encourages Start-Ups to Spark the Next Generation of Innovation and Collaboration in Mental Health Care 94

Dec 13, 2017: Otsuka Pharmaceutical Unveils It's Completely New Website 95

Appendix 96

Methodology 96

About GlobalData 96

Contact Us 96

Disclaimer 96

List of Figures

Otsuka Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Otsuka Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Otsuka Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Otsuka Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Otsuka Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Otsuka Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8

Otsuka Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Otsuka Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Otsuka Pharmaceutical Co Ltd, Medical Devices Deals, 2012 to YTD 2018 11

List of Tables

Otsuka Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Key Facts 2

Otsuka Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Otsuka Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Otsuka Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Otsuka Pharmaceutical Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 10

Otsuka Pharmaceutical Co Ltd, Medical Devices Deals, 2012 to YTD 2018 11

Otsuka Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Takara Bio Enters into Co-Development Agreement with Otsuka Pharma 16

Ribomic Enters into Agreement with Seikagaku 17

Medibio Enters into Agreement with Otsuka Pharma 18

Ribomic Enters into Research Agreement with Astellas Pharma 19

Ribomic Enters into Research Agreement with Evec 20

Cambridge Isotope Laboratories Enters into Agreement with IROA Technologies 21

Otsuka Pharma Enters into Co-Development Agreement with NEC 22

RIKEN and Otsuka Pharma Forms Joint Venture 23

Earth Chemical to Enter into Agreement with Taiko Pharma 24

Astex Pharma Enters into Agreement with Genentech 25

Ariad Pharma Enters into Co-Marketing Agreement with Otsuka Pharma for Iclusig 26

Ribomic Extends Research Agreement with Otsuka Pharma 28

Probi Enters into Co-Marketing Agreement with Pharmavite 29

Horizon Discovery Enters into Development and Commercialization Agreement with Otsuka Pharma 30

Otsuka Enters Into Co-Promotion Agreement With Takeda For TAK-438 31

Lundbeck Enters Into Co-Development Agreement With Otsuka Pharma For Lu AF20513 33

Lundbeck Enters Into Co-Development Agreement With Otsuka Pharma 34

Avanir Pharma Enters Into Agreement With Merck To Promote Diabetes Drugs 35

Otsuka Pharma Enters Into Co-Promotion Agreement Lundbeck For Abilify 37

Otsuka Pharma Forms Joint Venture With Abdi Ibrahim To Market Otsuka's Drugs In Turkey 38

Astex Pharma, Cancer Research Technology And Institute of Cancer Research Enter Into Epigenetic Drug Discovery Agreement 39

Otsuka Pharma Amends Co-Development Agreement With UCB 41

Otsuka Pharma Enters into Licensing Agreement with X-Chem 43

Mylan Pharma Enters into Licensing Agreement with Otsuka Novel Products for Delamanid 44

R-Pharm Enters into Licensing Agreement with Otsuka Novel Products 45

Otsuka Pharma Enters into Licensing Agreement with Teva Pharma for TEV-48125 46

Otsuka Pharma to Enter into Licensing Agreement with Ribomic for RBM001 47

Otsuka Pharma Enters into Licensing Agreement with Akebia Therapeutics for Vadadustat 48

Otsuka Pharma Enters into Licensing Agreement with Akebia Therapeutics 50

Otsuka Pharma Enters into Licensing Agreement with Takara Bio 51

Medimetriks Pharma Enters into Licensing Agreement with Otsuka Pharma for OPA-15406 52

NuView Life Sciences Enters into Licensing Agreement with Otsuka Pharma for VPAC1 Biomarker 53

Fujimoto Pharma Enters into Licensing Agreement with Ribomic 54

Lundbeck Enters Into Licensing Agreement With Otsuka Pharma For Lu AE58054 55

Concert Pharma Enters Into Licensing Agreement With AVANIR Pharma For Neurology And Psychiatry Drugs 56

Otsuka Pharma Enters Into Licensing Agreement With Eisai 58

Proteus Biomedical Enters Into Licensing Agreement With Otsuka Pharma 59

Otsuka Pharma Enters Into Licensing Agreement With Kyowa Hakko Kirin For Saxagliptin 60

Taiko Pharma to Raise Funds through Private Placement of Shares 61

Avanir Pharma Raises USD230 Million in Public Offering of Shares 62

Ribomic Raises USD26 Million in IPO of Shares 64

GlycoNex Announces Private Placement Of Shares For USD 9.2 Million 66

Avanir Pharma Files Registration Statement For Public Offering Of Securities For Up To USD 150 Million 67

Avanir Pharma Increases Size Of Private Placement Of Shares For USD 80 Million 68

Astex Pharma Files Registration Statement For Public Offering Of Securities For USD 200 Million 69

Tolero Pharma Acquires Drug Development Assets From Astex Pharma 71

Otsuka Pharma Acquires Visterra for USD430 Million 73

Otsuka Pharma to Acquire Neurovance 74

Otsuka Acquires Avanir Pharma for USD3.5 Billion 75

Egypt Otsuka Pharmaceutical to Acquire 80% Stake in Ateco Pharma 77

Otsuka Pharma Completes Acquisition Of Astex Pharma For USD 886 Million 78

Gimv Sells Stake In Astex Therapeutics 80

China Otsuka Pharmaceutical Acquires Dalian Taihua Pharmaceutical 81

Otsuka Pharmaceutical Co Ltd, Key Competitors 82

Otsuka Pharmaceutical Co Ltd, Key Employees 83

Otsuka Pharmaceutical Co Ltd, Other Locations 84

Otsuka Pharmaceutical Co Ltd, Subsidiaries 84

Otsuka Pharmaceutical Co Ltd, Joint Venture 90

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Otsuka Pharmaceutical Co Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 17835
Site License
USD 500 INR 35670
Corporate User License
USD 750 INR 53505

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com